Back to Search
JOHN PAGEL, MD PHD
MD PHD
Hematology & Oncology Physician
NPI: 1376633222Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
MD00037306(WA)
Research & Publications (20)
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
PMID 19118002·Cancer Res·2009
7-preclinical
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
PMID 19124831·Blood·2009
4-observational
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.
PMID 18042793·Blood·2008
7-preclinical
Radioimmunotherapeutic approaches for leukemia: the past, present and future.
PMID 18202970·Cytotherapy·2008
6-review
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
PMID 17575162·Cancer Res·2007
4-observational
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.
PMID 16254140·Blood·2006
3-trial
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
PMID 16556891·Blood·2006
4-observational
Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
PMID 16000584·Clin Cancer Res·2005
4-observational
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
PMID 12446461·Blood·2003
4-observational
The use of radioimmunoconjugates in stem cell transplantation.
PMID 12058230·Bone Marrow Transplant·2002
6-review
131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.
PMID 19332764·Blood·2009
7-preclinical
Validation of epithelial ovarian cancer and fallopian tube cancer and ovarian borderline tumor data in the Danish Gynecological Cancer Database.
PMID 19308749·Acta Obstet Gynecol Scand·2009
4-observational
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.
PMID 19515724·Blood·2009
4-observational
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
PMID 19244101·Cancer Res·2009
7-preclinical
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
PMID 18502830·Blood·2008
7-preclinical
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
PMID 18509084·Blood·2008
3-trial
High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
PMID 18623377·Cancer·2008
3-trial
The burden of obstructive sleep apnea and associated excessive sleepiness.
PMID 18687237·J Fam Pract·2008
6-review
Annual plants under cyclic disturbance regime: better understanding through model aggregation.
PMID 19263893·Ecol Appl·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1221 MADISON ST, SUITE 1020
SEATTLE, WA 98104 - Phone
- (206) 386-2267
Quick Facts
- NPI
- 1376633222
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile